Who is sponsoring NCT04122092?

NCT04122092 is sponsored by Shanghai Changzheng Hospital.

What drugs are being tested in NCT04122092?

Interventions in NCT04122092: The level of plasma cfDNA CINs.

What condition does NCT04122092 study?

NCT04122092 studies Multiple Myeloma.

Is NCT04122092 still recruiting?

NCT04122092 is currently status unknown. Last updated 18 November 2019.

Last reviewed 2019-11-18 · How we verify

NCT04122092: EUCADD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma

Status unknown Last updated 18 November 2019

What this trial tests

trial testing The level of plasma cfDNA CINs in Multiple Myeloma in 100 participants. Status unknown.

Timeline

20 October 2019

Primary endpoint
20 October 2021

20 October 2022

Quick facts

Lead sponsor	Shanghai Changzheng Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	20 October 2019
Primary completion	20 October 2021
Estimated completion	20 October 2022
Sites	1 location across China

Drugs / interventions tested

The level of plasma cfDNA CINs

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Shanghai Changzheng Hospital

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite the significantly higher complete remission rates and improved survival achieved over the last decade，multiple myeloma (MM) patients continue to relapse due to persistence of minimal residual disease (MRD). Currently, numerous studies have evaluated the prognostic value of MRD by detecting immunophenotypic and immunoglobulin (Ig) gene rearrangements from bone marrow aspiration samples. Here the investigators intend to study the clinical utility of Ultrasensitive Chromosomal Aneuploidy Detection (UCAD) as an MRD assay, which is based on plasma cell-free DNA(cfDNA) low-coverage whole-genome sequencing. UCAD is non-invasive and applicable for tumors with high heterogeneity and extramedullary invasions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.
Qiang W, Jin L, Luo T, Jia Y, et al · · 2023 · cited 4× · PMID 37669974 · DOI 10.1038/s41408-023-00904-9

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Shanghai Changzheng Hospital trials

Trials by the same sponsor.

NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04122092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
Last refreshed: 18 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing